Drugs in development for management of lipoprotein disorders
Authors:
- 1 March 2011
- journal article
- review article
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 5 (2) , 66-75
Abstract
No abstract availableFunding Information
- National Lipid Association
This publication has 24 references indexed in Scilit:
- Effect of Mipomersen, an Apolipoprotein B Synthesis Inhibitor, on Low-Density Lipoprotein Cholesterol in Patients With Familial HypercholesterolemiaThe American Journal of Cardiology, 2010
- Efficacy and Safety of Mipomersen, an Antisense Inhibitor of Apolipoprotein B, in Hypercholesterolemic Subjects Receiving Stable Statin TherapyJACC, 2010
- What's the deal with niacin development: is laropiprant add-on therapy a winning strategy to beat a straight flush?Current Opinion in Lipidology, 2009
- Design of the DEFINE trial: Determining the EFficacy and Tolerability of CETP INhibition with AnacEtrapibAmerican Heart Journal, 2009
- Abstract: 515 MBX8025, A NOVEL PPARΔ AGONIST: LIPID & METABOLIC EFFECTS IN DYSLIPIDEMIC OVERWEIGHT PATIENTSAtherosclerosis Supplements, 2009
- Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetesNature Reviews Drug Discovery, 2009
- Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patientsAmerican Heart Journal, 2009
- Effects of Torcetrapib in Patients at High Risk for Coronary EventsNew England Journal of Medicine, 2007
- A double-blind, randomised trial of tesaglitazar versus pioglitazone in patients with type 2 diabetes mellitusDiabetes & Vascular Disease Research, 2007
- Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trialThe Lancet, 2007